BPTH Bio-Path: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The 12-month YoY percentage change in EPS for Bio-Path Holdings (BPTH) reflects current dynamics, with the value fixed at -5.70. In the absence of profit, share prices depend on the success of liposomal developments. Expenses have been optimized by outsourcing production to external cGMP plants, while the team consists of leading biologists attracted by stock options and the opportunity to work on cutting-edge DNA therapy methods.

Bio-Path Holdings (BPTH) is developing unique therapies for aggressive hemoblastoses, leveraging exclusive patent developments. Year-over-year EPS growth (TTM) measures earnings per share dynamics, reflecting the revaluation of discounted cash flows via the weighted average cost of capital (WACC). This indicator enables an assessment of the business's fundamental value under strict FDA oversight. Analyzing this metric helps avoid overpaying for an asset during a stage of decelerating expansion. The current annual EPS TTM growth value serves as a filter to verify the company's long-term financial potential.